Study Design. Prospective randomized trial.
lack of normal sensitivity. 6, 7 It has been shown that compression of the spinal nerve roots may induce neurophysiologic dysfunction, degeneration, and reduced blood flow in nerve roots in both animal models and humans. 6, 7 Recently, cytokines such as interleukins 1, 6 (IL-1, IL-6), and tumor necrosis factor-alpha (TNF-a) have been strongly linked to radicular pain. 2, 7, 8 It has also been reported that IL-1, IL-6, and TNF-a are activated in dorsal root ganglia and Schwann cells in the spinal nerve roots following lumbar spinal stenosis, and that their expression is closely related to pain, motor nerve dysfunction and degeneration. 3, 7 In animal models, the TNF-a inhibitors, infliximab (intravenous injection) and etanercept (subcutaneous injection), have prevented a nucleus pulposus-induced reduction of nerve conduction velocity and also seemed to limit nerve fiber injury, intracapillary thrombus formation, and intraneural edema. 9 In the clinic, inhibition of TNF-a has become a common modality for treating rheumatoid disease. It has been reported that a single intravenous infusion of infliximab was effective in treating sciatic pain caused by lumbar disc herniation. 10 On the other hand, intravenous infusion of infliximab was compared to a placebo by a Finnish group that conducted the first randomized controlled trial of this inhibitor. The results were disappointing. 11, 12 Cohen et al. have reported a preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica caused by disc herniation in 24 patients. They found effectiveness was dependent on the dose of etanercept (4 groups). 13 In the clinical arm of the study, significant improvements in leg and back pain were collectively noted for the etanercept-treated patients one The purpose of the current study was to examine the effect on radicular pain of epidural administration of the TNF-a inhibitor, etanercept, onto spinal nerves in patients with lumbar spinal stenosis. We compared application of the TNF-a inhibitor, etanercept, with application of dexamethasone for the treatment of pain.
Methods
The ethics committee of our institution approved the protocol for the human procedures used in this study and informed written consent was obtained from each subject.
Patients
Patients had low back and leg pain, continuing for at least 1 month. Patients who had previously undergone spinal surgery were excluded from the study. We also excluded patients with spinal tumor, infection, or trauma. Patients were diagnosed with lumbar spinal stenosis on X-ray and magnetic resonance imaging (MRI) and by physical examination. Diagnosis by X-ray was spondylosis and spondylolisthesis (more than 3 mm of anterior slip in a normal position). The degree of spinal stenosis varied from slight to severe. MRI showed central stenosis, stenosis of the lateral recess, and foraminal stenosis. We measured degree of stenosis in case of stenosis of the lateral recess and central stenosis and classified it as: >0% to ≤30%, slight stenosis; >30% to ≤70%, moderate stenosis; >70% to ≤100%, severe stenosis. Most patients diagnosed as having stenosis of the lateral recess fell into the category of slight stenosis in the current study. Details are shown in Table 1 infiltration was performed to confirm the finding. Patients were allowed nonsteroidal anti-inflammatory drugs (NSAIDs) to control low back pain and leg pain.
Epidural administration
The patients were divided randomly into 2 groups. The patients were randomized according to the minimization method for injection using etanercept or injection using dexamethasone. 14 We employed sex and age as stratification factors. 
Pain scores
We evaluated the change in low back and leg pain before and after epidural administration. To evaluate pain, the visual analogue scale (VAS) score (0, no pain; 10, worst pain) was recorded before and 30 minutes, 3 days, 1 week, 2 weeks, and 4 weeks after epidural administration.
Oswestry Disability Index (ODI) scores were recorded before and 4 weeks after epidural administration.
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Subjective Outcomes
At 4 weeks after injection, patients were asked to choose one of the following responses regarding their satisfaction with the treatment: (1) treatment met my expectations; (2) I did not improve as much as I had hoped, but I would undergo the same treatment for the same outcome;
(3) treatment helped, but I would not undergo the same treatment for the same outcome; or (4) I am the same as or worse than I was before the treatment.
Complications
Deep or superficial infection including respiratory infection in both groups was evaluated. Spinal nerve injury (motor palsy or sensory disturbance) or other complications in both groups were also evaluated.
Statistical Analysis
Data were compared using a Kruskal-Wallis test to compare pain scales between the two groups, a one-way ANOVA with post hoc comparisons for age, symptom duration, and follow-up; and Fisher's test was used for dichotomous/categorical variables. P < 0.05 was considered statistically significant.
Results
Demographic characteristics of patients in both the etanercept and dexamethasone groups are shown in Table 1 . There was no significant difference in VAS score (leg pain, low back pain, leg numbness) and ODI score between the 2 groups (P > 0.05). There was no significant difference in the number of the patients who used NSAIDs between the 2 groups (P > 0.05). Affected spinal nerves were mainly in L5 spinal nerves in both groups.
In both groups, treatment was significantly effective in attenuating leg pain, leg numbness, and low back pain 30 min after injection (P < 0.05) (Figures 1, 2, and 3 ). For leg pain in both groups, treatment was significantly effective in attenuating the pain during the 4 weeks of testing (P < 0.05) (Figure 1 ). VAS scores of leg pain in the etanercept group were significantly lower than those in the dexamethasone group at 3 days, and 1, 2, and 4 weeks (P < 0.05) (Figure 1 ).
For leg numbness, treatment was significantly effective in attenuating the pain during the 4 weeks in both groups (P < 0.05) ( Figure 2 ). VAS scores of leg numbness in the etanercept group were significantly lower than those in the dexamethasone group at 3 days, and 1, and 2 weeks (P < 0.05) (Figure 2 ).
Both epidural administrations were effective for low back pain (VAS) in both group during the 4 weeks (P<0.05) (Figure 3 ). VAS scores of low back pain in the etanercept group were significantly lower than those in the dexamethasone group at 3 days, and 1, and 2 weeks (P < 0.05) (Figure 3 ).
There was no significant difference in ODI scores before epidural administration between the groups (P > 0.05). The average ODI score decreased at 4 weeks, and there was significant improvement in both groups compared with before epidural administration (P < 0.05) ( Table 1 and 3). However, there was no significant difference in ODI score between the etanercept and dexamethasone groups at 4 weeks (P > 0.05) ( Table 3 ).
Details of subjective outcomes 4 weeks after injection are presented in Table 4 . Subjective outcomes for most patients in both groups were good or fair; however, 6 patients in the etanercept group and 11 patients in the dexamethasone group reported an unexpected or poor outcome. Table 5 shows complications, from injection through 4 weeks of follow-up. There was no respiratory infection, deep, or superficial infection in either group. There was no spinal nerve injury or other complications in either group.
Complications

Discussion
In the current study, results indicate that single epidural administration of a TNF-a inhibitor onto the spinal nerve produced significantly more pain relief than application of dexamethasone, and produced no adverse event. TNF-a may mediate the radicular pain caused by spinal stenosis in humans.
It has also been reported that TNF-a is activated in dorsal root ganglia and Schwann cells in the spinal nerve roots following lumbar spinal stenosis, and is closely related to pain. 3, 7 In human studies, the concentration of TNF-a has been found to be high in synovium in facet joints in lumbar spinal stenosis patients compared with lumbar disc herniation patients, thus suggesting that TNF-a in degenerated facet joints may be related to the cause of pain in degenerative lumbar disorders. 15 Recently, two types of TNF-a inhibitors, infliximab and etanercept, have been used to treat radicular leg pain in animal and human studies. Intraperitoneal injection of infliximab prevents nucleus pulposus-induced histologic changes in the rat DRG. 16 Treatment with infliximab significantly reduced pain-related behavior in rats. 4 Etanercept prevented nerve degeneration. 9 It has recently been reported that intravenous injection of infliximab is clinically effective in treating sciatic pain caused by lumbar disc herniation. 10 On the other hand, the effect of intravenous injection of infliximab was examined in a randomized controlled trial, and found not to be effective. 11, 12 These studies in animal models and in humans are controversial, and the effect of direct application of TNF-a inhibitor onto damaged nerves including those found in spinal stenosis has not been fully explored.
Several authors have reported that the effects of direct application of a TNF-a inhibitor onto spinal nerves affected disc herniation in animals and humans. Norimoto et al. have reported that nucleus pulposus application onto crushed sciatic nerves produced mechanical allodynia;
however, epidural administration of a TNF-a inhibitor (etanercept) onto the sciatic nerve did not suppress pain-related behavior. 17 Cohen et al. have reported a study in which 24 patients with subacute lumbosacral radiculopathy caused by disc herniation were randomly assigned to receive two transforaminal epidural injections of 2, 4, or 6 mg of etanercept, and significant improvements in leg and back pain were noted for the etanercept-treated patients, but not for the saline-treated control group, at one month after treatment. No adverse event was reported. 13 In the current study, we showed that epidural administration of a TNF-a inhibitor onto spinal nerves relieved pain caused by spinal stenosis. We concluded that TNF-a may play a crucial role in pain caused by both lumbar disc herniation and spinal stenosis. VAS scores of low back pain in the etanercept group were significantly lower than those in the dexamethasone group during a 2-week follow-up. However, there was no significant difference in ODI scores between the etanercept and dexamethasone groups at 4 weeks. In this regard, single application of 10 mg of etanercept had a relatively short term effect for low back pain.
In the current study, we compared lidocaine+etanercept with lidocaine+dexamethasone. The efficacy of steroids for nerve root injection has been reported. Fifty-five patients who were deemed to be surgical candidates were treated and randomized to receive either a selective nerve root injection of betamethasone 6 mg with bupivacaine or a selective nerve root injection of bupivacaine alone. This study showed that 67% of patients in the group receiving both local anesthetic and steroid avoided the need for surgical intervention, compared with 28% in the group receiving local anesthetic alone. 18 A systematic review of therapeutic lumbar transforaminal epidural steroid therapy has shown that the indicated evidence for transforaminal lumbar epidural steroid injections is both short-and long-term pain relief compared with local anesthetic alone. 19 In the current study, we showed that application of etanercept produced significantly more pain relief than application of dexamethasone alone. We did not examine a lidocaine only group; however, etanercept is probably more effective for pain than application of lidocaine alone by analogy with the previous studies.
It is not clear whether systemic or direct administration of the inhibitor is the most effective route. In previous reports, intravenous injection of infliximab was effective or ineffective in treating sciatic pain caused by lumbar disc herniation 10, 11, 12 TNF-a is mainly expressed around or in the disc tissue, where blood supply is generally considered to be insufficient. Therefore we believe that the supply of TNF-a inhibitors is insufficient in case of systemic administration. It is also known that TNF-a inhibitors can have adverse effects when administered in high doses systemically. 18 It is not known if these effects occur after direct administration to nerve; 2) I did not improve as much as I had hoped, but I would undergo the same treatment for the same outcome 12 12 3) Treatment helped, but I would not undergo the same treatment for the same outcome 
